K.A. (Kim) Neve '75             Bibliography

Publications:

 1.   Neve KA, Kozlowski MR, and Marshall JF, Plasticity of neostriatal dopamine receptors after nigrostriatal injury:  Relationship to recovery of sensorimotor functions and behavioral supersensitivity, Brain Research 244 (1982) 33-44.

 2.   Marshall JF, Drew MC, and Neve KA, Recovery of function after mesotelencephalic dopaminergic injury in senescence, Brain Research 259 (1983) 249-260.

 3.  Kozlowski MR, Neve KA, Grisham JE, and Marshall JF, Chronic lithium administration alters behavioral recovery from nigrostriatal injury:  Effects on neostriatal 3H-spiroperidol binding sites, Brain Research 267 (1983) 301-311.

 4.   Altar CA, Neve KA, Loughlin SE, Marshall JF, and Fallon JH, The crossed mesostriatal projection:  neurochemistry and developmental response to lesion, Brain Research 279 (1983) 1-8.

 5.   Neve KA, Altar CA, Wong CA, and Marshall JF , Quantitative analysis of 3H-spiroperidol binding to rat forebrain sections:  Plasticity of neostriatal dopamine receptors after nigrostriatal injury, Brain Research 302 (1984) 9-18.

 6.   Altar CA, Walter RJ, Neve KA, and Marshall JF, Computer-assisted video analysis of 3H-spiroperidol autoradiography, Journal of Neuroscience Methods 10 (1984) 173-188.

 7.   Neve KA and Marshall JF, The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive, Neuroscience Letters 46 (1984) 77-83.

 8.   Neve KA, Loeschen S, and Marshall JF, Denervation accelerates the reappearance of neostriatal D-2 receptors after irreversible receptor blockade, Brain Research 329 (1985) 225-231.

 9.   Neve KA, Barrett DA, and Molinoff PB, Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists, Journal of Pharmacology and Experimental Therapeutics 235 (1985) 657-664.

10.  Neve KA, McGonigle P, and Molinoff PB, Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors, Journal of Pharmacology and Experimental Therapeutics 238 (1986) 46-53.

11.  Neve KA and Molinoff PB, Turnover of ß1- and ß2-adrenergic receptors after down-regulation or irreversible blockade, Molecular Pharmacology 30 (1986) 104-111.

12.  McGonigle P, Neve KA, and Molinoff PB, A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes, Molecular Pharmacology 30 (1986) 329-337.

13.  Luedtke RR, Korner M, Neve KA, and Molinoff PB, Monoclonal antibodies with high affinity for spiroperidol, Journal of Neurochemistry 50 (1988) 1253-1262.

14.  Neve KA and Casey DE, Development and characterization of anti-spiroperidol antibodies, Biochemical Pharmacology 37 (1988) 3204-3206.

15.  Abramson SN, Martin MW, Hughes AR, Harden TK, Neve KA, Barrett DA, and Molinoff PB, Interaction of ß-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc- S49 lymphoma cells, Biochemical Pharmacology 37 (1988) 4289-4297.

16.  Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, and Civelli O, Cloning and expression of a rat D2 dopamine receptor cDNA, Nature 336 (1988) 783-787.

17.  Neve KA, Henningsen RA, Bunzow JR, and Civelli O, Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line, Molecular Pharmacology 36 (1989) 446-451.

18.  Albert PR, Neve KA, Bunzow JR, and Civelli O, Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylate cyclase and prolactin secretion, Journal of Biological Chemistry 265 (1990) 2098-2104.

19.  Neve KA, Henningsen RA, Kinzie JM, de Paulis T, Schmidt DE, Kessler RM, and Janowsky A, Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand, Journal of Pharmacology and Experimental Therapeutics 252 (1990) 1108-1116.

20.  Machida CA, Bunzow JR, Searles RP, Van Tol HHM, Tester B, Neve KA, Teal P, Nipper V, and Civelli O, Molecular cloning and expression of the rat ß1-adrenergic receptor gene, Journal of Biological Chemistry 265 (1990) 12960-12965.

21.  Neve KA, Regulation of dopamine D2 receptors by sodium and pH, Molecular Pharmacology 39 (1991) 570-578.

22.  Neve KA, Neve RL, Fidel S, Janowsky A, and Higgins GA, Increased abundance of alternatively spliced variants of dopamine D2 receptor mRNA after denervation, Proceedings of the National Academy of Science USA 88 (1991) 5602-5608.

23.  Neve KA, Cox BA, Henningsen RA, Spanoyannis A, and Neve RL, Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase, Molecular Pharmacology 39 (1991) 733-739.

24.  Joyce JN, Janowsky A, and Neve KA, Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain, Journal of Pharmacology and Experimental Therapeutics 257 (1991) 1253-1263.

25.  Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, and Belknap JK, Extrastriatal dopamine D2 receptors:  Distribution, pharmacological characterization, and region-specific regulation by clozapine, Journal of Pharmacology and Experimental Therapeutics 261 (1992) 1282-1290.

26.  Machida CA, Searles RP, Nipper V, Kozell LB, and Neve KA, Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene, Molecular Pharmacology 41 (1992) 652-659.

27.  Cox BA, Henningsen RA, Spanoyannis A, Neve RL, and Neve KA, Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors, Journal of Neurochemistry 59 (1992) 627-635.

28.  Neve KA, Kozlowski MR, and Rosser MP, Dopamine D2 receptor stimulation of Na+/H+ exchange assessed by quantification of extracellular acidification, Journal of Biological Chemistry 267 (1992) 25748-25753.

29.  Ivins KJ, Neve KA, Feller DJ, Fidel SA, and Neve RL, Antisense GAP-43 inhibits the evoked release of dopamine from PC12 cells, Journal of Neurochemistry 50 (1993) 626-633.

30.  Neve RL, Ivins KJ, Neve KA, Bahr BA, Vanderklish PW, Arai A, and Lynch G, The use of antisense intervention to decipher the role of the neuronal growth associated protein GAP-43, NeuroProtocols 2 (1993) 29-49.

31.  Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB, Hexahydrobenzo[a]phenanthridines:  novel D3 dopamine receptor ligands, European Journal of Pharmacology 239 (1993) 271-273.

32.  Eshleman AJ, Henningsen RA, Neve KA, and Janowsky A, Release of dopamine via the human transporter, Molecular Pharmacology 45 (1994) 312-316.

33.  Kozell LB, Machida CA, Neve RL, and Neve KA, Chimeric D1/D2 dopamine receptors:  Distinct determinants of selective potency, efficacy, and signal transduction,  Journal of Biological Chemistry 269 (1994) 30299-30306.

34.  Eshleman AJ, Neve RL, Janowsky A, and Neve KA, Characterization of a recombinant human dopamine transporter expressed in multiple cell lines.  Journal of Pharmacology and Experimental Therapeutics 274 (1995) 276-283.

35.  Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, and Mailman RB, LSD and structural analogs:  Pharmacological evaluation at D1 dopamine receptors, Psychopharmacology 118 (1995) 401-409.

36.  Starr S, Kozell LB, and Neve KA, Drug-induced up-regulation of dopamine D2 receptors on cultured cells,  Journal of Neurochemistry 65 (1995) 569-577.

37.  Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, and Neve KA, Regulation and functional characterization of a rat recombinant dopamine D3 receptor, Synapse 21 (1995) 1-9.

38.  Brusniak M-YK, Pearlman RS, Neve KA, and Wilcox RE, Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors. Journal of Medicinal Chemistry 39 (1996) 850-859.

39.  Watts VJ and Neve KA, Sensitization of endogenous and recombinant adenylate cyclase by activation of D₂ dopamine receptors, Molecular Pharmacology 50 (1996) 966-976.

40.  Eshleman AJ, Stewart E, Evenson AK, Mason J, Janowsky A, and Neve KA, Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters, Journal of Neurochemistry 69 (1997) 1459-1466.

41.  Watts VJ and Neve KA, Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors, Molecular Pharmacology 52 (1997) 181-186.

42.  Kozell LB and Neve KA, Constitutive activity of a chimeric D2/D1 dopamine receptor, Molecular Pharmacology 52 (1997) 1137-1149.

43.  Johnson RA, Eshleman AJ, Myers T, Neve KA, and Janowsky A, [3H]Substrate- and cell-specific effect of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux, Synapse 30 (1998) 97-106.

44. Song S, Wang Y, Bak S-Y, During MJ, Bryan J, Ashe O, Ullrey DB, Trask LE, Grant FD, O’Malley KL, Riedel H, Goldstein DS, Neve KA, LaHoste GJ, Marshall JF, Haycock JW, Neve RL, and Geller AI, Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons, Journal of Neuroscience, 18 (1998) 4119-4132. 

45. Luo Y, Kokkonen GC, Wang X, Neve KA, and Roth GS, D2 dopamine receptors stimulate mitogenesis through PTX-sensitive G proteins and Ras involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells, Journal of Neurochemistry 71 (1998) 980-990.

46. Wilcox RE, Ginsburg B, Tseng T, Brusniak M-Y K, Pearlman RS, Teeter M, DuRand C, Starr S, and Neve KA, CoMFA-based prediction of agonist affinities at recombinant D1 vs. D2 dopamine receptors, Journal of Medicinal Chemistry 41 (1998) 4385-4399.

47. Wiens BL, Nelson CS, and Neve KA, Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor:  evidence for multiple, agonist-specific active conformations, Molecular Pharmacology 54 (1998) 435-444.

48. Watts VJ, Wiens BL, Cumbay MG, Vu M, Neve RL, and Neve KA, Selective activation of Gao by D2L dopamine receptors in NS20Y neuroblastoma cells, Journal of Neuroscience 18 (1998) 8692-8699.

49. Eshleman AJ, Carmolli M, Cumbay M, Neve KA, and Janowsky A, Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type, Journal of Pharmacology and Experimental Therapeutics 289 (1999) 877-885.

50. Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HHM, and Neve KA,  Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors, Psychopharmacology 141 (1999) 83-92.

51. Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, and Mader SL,  Viral-mediated gene delivery of constitutively activated Gas alters vasoreactivity, Clinical and Experimental Pharmacology and Physiology, 27 (2000) 9-13.

52. Wilcox RE, Huang W-H, Wilcox DM, Brusniak M-YK, Pearlman RS, Teeter MM, DuRand CJ, Wiens BL, and Neve KA,  CoMFA-based prediction of agonist affinities at recombinant wildtype vs. serine to alanine point mutated D2 dopamine receptors.  Journal of Medicinal Chemistry 43 (2000) 3005-3019.

53. Nelson CS, Ikeda M, Gompf HS, Robinson ML, Fuchs NK, Yoshioka T, Neve KA, and Allen CN,  Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124.  Molecular Endocrinology 15 (2001) 1306-1317.

54. Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, and Teeter MM,  Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor.  Molecular Pharmacology 60 (2001) 373-381.

55. Watts VJ, Taussig R, Neve RL, and Neve KA, Dopamine D2 receptor-induced heterologous sensitization of adenylate cyclase requires Gas:  Characterization of Gas-insensitive mutants of adenylate cyclase V.  Molecular Pharmacology 60 (2001) 1168-1172.

56. Mason JN, Kozell LB, and Neve KA, Regulation of dopamine D1 receptor trafficking by protein kinase A-dependent phosphorylation.  Molecular Pharmacology 61 (2002) 806-816.

Reviews, Invited Papers, and Books:

1.    Neve KA and Molinoff PB, Effects of chronic administration of agonists and antagonists on the density of ß-adrenergic receptors, American Journal of Cardiology 57 (1986) 17F-22F.

2.    Civelli O, Bunzow J, Van Tol H, Grandy D, Albert P, Salon J, Machida C, and Neve K, Cloning of a rat D2-dopamine receptor cDNA, in Molecular Biology of Neuroreceptors and Ion Channels (Maelicke, A., ed.) NATO ASI Series H: Cell Biology, Vol. 32, Springer Verlag (1989) 259-267.

3.    Neve KA, Henningsen RA, Cox BA, Kozell LB, and Neve RL, Structure-function analysis of dopamine D2 receptors by in vitro mutagenesis.  In:  Dopamine Receptors and Transporters (Niznik, HB, ed.), Marcel Dekker, Inc. (1994) 299-322.

4.    Neve RL and Neve KA, Receptor expression in mammalian cells.  In:  Receptor Molecular Biology (Sealfon SC, Ed.) Methods in Neurosciences Vol. 25 (1995) 163-174.

5.    Neve KA, Rosser MP, and Barber DL, Regulation of Na+-H+ exchange by G protein-coupled receptors.  In:  Receptor Molecular Biology (Sealfon SC, Ed.) Methods in Neurosciences Vol. 25 (1995) 225-241.

6.    Neve KA and Wiens BL, Four ways of being an agonist:  Multiple sequence determinants of efficacy at D2 dopamine receptors, Biochemical Society Transactions 23 (1995) 112-116.

7.    The Dopamine Receptors (Neve KA and Neve RL, Eds.), a volume of The Receptors (Bylund DB, Series Ed.) Humana Press, 1997.

8.    Neve KA and Neve RL,  Molecular biology of dopamine receptors.  In:  The Dopamine Receptors (Neve KA and Neve RL, Eds.) Humana Press (1997) pp. 27-76.

9.    Sibley DR and Neve KA,  Regulation of dopamine receptor function and expression.  In:  The Dopamine Receptors (Neve KA and Neve RL, Eds.) Humana Press (1997) pp. 383-424.

10.   Neve KA,  Commentary on Mini-Review by Seeman P, Corbett R, and Van Tol HHM, Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4.  Neuropsychopharmacology 16 (1997) 111-113.

11.   Neve RL and Neve KA, Overview of neural gene expression.  In:  Current Protocols in Neuroscience (Crawley J, Gerfen C, McKay R, Rogawski M, Sibley D, and Skolnick P, Eds.) Wiley & Sons (1997) 4.5.1 - 4.5.4.

12.   Neve KA and Neve RL, Stable expression of G protein-coupled receptors in mammalian cells.  In:  Identification and Expression of G Protein-Coupled Receptors (Lynch K, Volume Ed.) in the Series Receptor Biochemistry and Methodology (Sibley DR and Strader CA, Series Eds.) Wiley & Sons (1998) 97-112.

13.   Janowsky A, Neve KA, and Eshleman AJ, Uptake and release of neurotransmitters.  In: Current Protocols in Neuroscience (Crawley J, Gerfen C, McKay R, Rogawski M, Sibley D, and Skolnick P, Eds.) Wiley & Sons (1998) 7.9.1 - 7.9.22.

14.   Neve KA, DuRand CJ, and Teeter MM, Structural analysis of the mammalian D2, D3, and D4 dopamine receptors  In:  Dopamine Receptors and Transporters , 2^nd edition (Sidhu A, Laruelle M, and Vernier P, editors.), Marcel Dekker, Inc., In Press.